ASPEN PHAR.UN.ADR /1 O.N. Cash Flow-to-Debt Ratio
ASPEN PHAR.UN.ADR /1 O.N. cash flow-to-debt ratio. ASPEN PHAR.UN.ADR /1 O.N. (LDZU) has a Cash Flow-to-Debt Ratio of 0.10x as of June 2025, meaning its operating cash flow of €5.16 Billion could theoretically repay 0% of its total liabilities (€51.00 Billion) in one year. Check LDZU total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ASPEN PHAR.UN.ADR /1 O.N. (2022–2025)
Cash flow-to-debt ratio of ASPEN PHAR.UN.ADR /1 O.N. from 2022 to 2025. Historical debt coverage capacity for ASPEN PHAR.UN.ADR /1 O.N. across 4 annual periods. Check ASPEN PHAR.UN.ADR /1 O.N. (LDZU) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
ASPEN PHAR.UN.ADR /1 O.N. Cash Flow-to-Debt Ratio by Year (2022–2025)
ASPEN PHAR.UN.ADR /1 O.N. cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for ASPEN PHAR.UN.ADR /1 O.N.. For the full cash flow conversion analysis, see ASPEN PHAR.UN.ADR /1 O.N. cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | €5.16 Billion | €51.00 Billion | ▼ -11.9% |
| 2024 | 0.11x | €6.22 Billion | €54.20 Billion | ▼ 0.0% |
| 2023 | 0.11x | €5.52 Billion | €48.05 Billion | ▼ -13.6% |
| 2022 | 0.13x | €5.37 Billion | €40.43 Billion | — |